AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
13.25
-0.15 (-1.12%)
Jun 29, 2026, 10:55 AM EDT - Market open
AngioDynamics Employees
AngioDynamics had 675 employees as of May 31, 2025. The number of employees decreased by 73 or -9.76% compared to the previous year.
Employees
675
Change (1Y)
-73
Growth (1Y)
-9.76%
Revenue / Employee
$464,778
Profits / Employee
-$46,499
Market Cap
552.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| May 31, 2025 | 675 | -73 | -9.76% |
| May 31, 2024 | 748 | -67 | -8.22% |
| May 31, 2023 | 815 | 55 | 7.24% |
| May 31, 2022 | 760 | -40 | -5.00% |
| May 31, 2021 | 800 | 0 | - |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Azenta | 2,900 |
| Embecta | 1,850 |
| AtriCure | 1,350 |
| STAAR Surgical Company | 921 |
| OraSure Technologies | 500 |
| Anteris Technologies Global | 174 |
| BioLife Solutions | 155 |
| Utah Medical Products | 152 |
ANGO News
- 12 days ago - AngioDynamics receives FDA IDE approval for RELIEF feasibility study - TheFly
- 12 days ago - AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH) - Business Wire
- 19 days ago - AngioDynamics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 19 days ago - AngioDynamics Slides: FY 2026 - Filings
- 4 weeks ago - AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect - Business Wire
- 4 weeks ago - AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 4 weeks ago - 3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026 - TipRanks
- 6 weeks ago - AngioDynamics announces two-year PRESERVE trial data - TheFly